German pharma firm buys €80m C3 to boost its European cannabis presence

This story examines the significance of German pharma group Dermapharm’s acquisition of the Germany based Cannabinoid Compound Company (C3) from Canadian owner Canopy Growth. We show how it’s an opportunity for Dermapharm to expand in the European medical cannabis market, but represents a considerable loss for Canopy after only three years’ ownership.

Read full article
I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization